The report "Mice Model Market by Model Types (Inbred, Outbred, Hybrid), Services (Breeding, Rederivation), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology, Immunology), Application (Research, Drug Discovery) - Global Forecast to 2029", is projected to reach USD 2.2 billion by 2029 from an estimated USD 1.5 billion in 2024, at a CAGR of 8.1% during the forecast period.
Browse 496 market data Tables and 46 Figures spread through 386 Pages and in-depth TOC on "Mice Model Market by Model Types (Inbred, Outbred, Hybrid), Services (Breeding, Rederivation), Technology (Microinjection, CRISPR/Cas9), Therapeutic Area (Oncology, Neurology, Immunology), Application (Research, Drug Discovery) - Global Forecast to 2029"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/mice-model-market-1308.html
The rise in chronic diseases, such as cancer, diabetes, and cardiovascular disorders, and growing need for reliable and predictive animal models to facilitate drug discovery and development are the major driving factors of the mice model market. However, the presence of alternative research models, and recent guidelines of U.S.FDA on restriction animal models can hamper market growth.
The inbred mice segment accounted for the largest share by model type in the mice model market in 2023.
By model type, the mice model market has been further categorized into inbred mice, genetically engineered mice, hybrid/congenic mice, and outbred mice. Inbred mice accounted for the largest share of the mice model market in 2023. The pivotal role played by genetic uniformity provides consistency and reproducibility, making them ideal for studying complex traits and diseases, contributes significantly to the expansion of this segment within the mice model market.
The CRISPR/Cas9 segment is expected to grow at a higher rate during the forecast period.
Based on technology, the mice model market has been segmented into CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies. In 2023, the CRISPR/Cas9 segment accounted for the largest share of the mice model market is expected to grow at a higher growth rate during the forecast period of 2024-2029. CRISPR technology offers a cost-effective solution for generating genetically modified mice compared to traditional methods such as embryonic stem cell-based targeting.
The oncology segment accounted for the largest share of the therapeutic area segment in the mice model market in 2023.
Based on therapeutic area, the mice model market is segmented into oncology, neurology, metabolic diseases, immunology, cardiovascular diseases, and other diseases. In 2023, oncology accounted for the largest share of the mice model market. The expansion of the oncology mice model market is fueled by a surge in research funding dedicated to the advancement of personalized drug products for cancer treatment. For instance, the National Cancer Institute (NCI) allocated an estimated USD 6,467 million from its research budget, covering diverse disease areas such as AIDS, brain & CNS, and cancer.
The North America region accounted for the largest share of the mice model market in 2023.
The mice model market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. The North America region is witnessing increasing investments and research activities in the field of drug discovery and development. The need for advanced therapies due to rising rate of cancer and other chronic diseases has contributed to growth of the mice model market.
Key players in the mice model market Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland).
About MarketsandMarkets™ MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report. MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe. Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem. The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing. Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts. In addition, MarketsandMarkets SalesIQ enables sales teams to identify high-priority accounts and uncover hidden opportunities, helping them build more pipeline and win more deals with precision. To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.
Comments (0)